I-Mab has dosed the first subject in China in a Phase I clinical trial of antibody, TJ-CD4B (ABL111), for individuals with solid tumours, including gastric cancer, gastroesophageal junction carcinoma, oesophageal adenocarcinoma, and pancreatic ductal carcinoma.

The first bispecific antibody of its drug class in the clinical stage, TJ-CD4B is a new Claudin 18.2 x 4-1BB bispecific antibody.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It attaches to cancer cells expressing Claudin 18.2 and co-stimulatory molecule 4-1BB on T cells to offer a tumour-killing effect. 

I-Mab is developing the antibody in partnership with South Korean clinical-stage biotechnology firm ABL Bio.

The global, multicentre trial will analyse the potential of TJ-CD4B in cancer patients for various malignancies that do not have effective treatments presently.

In preclinical studies, the antibody showed the potential to be an effective therapy option. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, it has a wider anti-tumour effect on tumours expressing reduced Claudin 18.2 levels.

Apart from the trial in China, TJ-CD4B/ABL111 is being analysed in a Phase I trial in the US.

I-Mab president Dr Andrew Zhu said: “TJ-CD4B, powered by 4-1BB-activation platform, is a promising asset of the company’s highly innovative bispecific antibody pipeline and represents the new generation of I-Mab’s continued innovation. 

“This asset has the potential to treat highly challenging cancers such as gastric cancer, one of the most prevalent cancer types in China and an illness that often suffers from poor prognosis.”

In June this year, the company concluded enrolment of participants in the Phase III TALLER trial of eftansomatropin alfa (TJ101) to treat paediatric growth hormone deficiency in China.